Northpond Ventures, a science-driven venture capital firm, led a $85m Series B funding round in Kyverna Therapeutics, a cell therapy company, with participation from Westlake Village BioPartners , Vida Ventures, Gilead Sciences, RTW Investments, CAM Capital, Insight Partners, HealthCor, LYFE Capital, Intellia Therapeutics, Argentum Peak, Hudson Bay Capital and jVen Capital. "This financing reflects significant investor confidence in the science behind Kyverna’s cell therapies, world-class team, and commitment to bringing new therapies to patients suffering from serious autoimmune diseases," Ian Clark, Kyverna Chair of Board of Directors.